The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study

The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study

Ritonavir-boosted darunavir (DRV/r) and dolutegravir (DTG) are affected by induction of metabolizing enzymes and efflux transporters caused by rifampicin (RIF). This complicates the treatment of people living with HIV (PLWH) diagnosed with tuberculosis. Recent data showed that doubling DRV/r dose di...

Full description

Bibliographic Details
Main Authors:	Calcagno, A. (Author), D'Avolio, A. (Author), De Nicolò, A. (Author), De Vivo, E. (Author), Di Perri, G. (Author), Ebrahim, I.-E (Author), Maartens, G. (Author), McIlleron, H. (Author), Motta, I. (Author), Orrell, C. (Author), Wiesner, L. (Author)
Format:	Article
Language:	English
Published:	NLM (Medline) 2022
Subjects:	darunavir dolutegravir drug interactions drug-drug interaction PBMC pharmacokinetics rifampicin
Online Access:	View Fulltext in Publisher

Similar Items

Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance
by: Eva Wolf, et al.
Published: (2021-09-01)

A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data
by: Amedeo F. Capetti, et al.
Published: (2017-09-01)

Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy
by: Kairoonisha Mahomed, et al.
Published: (2020-07-01)

Pharmacokinetic interactions between rifampicin and efavirenz in HIV-TB coinfections
by: Yenny
Published: (2009-12-01)

Pharmacokinetic interactions between rifampicin and efavirenz in HIV-TB coinfections
by: Yenny Yenny
Published: (2016-02-01)

Effects of rifampicin and ketoconazole on the pharmacokinetics of a single oral dose of diethylcarbamazine in healthy volunteers
by: W Ridtitid, et al.
Published: (2006-12-01)

Effect of coadministration of rifampicin on the pharmacokinetics of linezolid: clinical and animal studies
by: Satsuki Hashimoto, et al.
Published: (2018-11-01)

Will Drug Resistance against Dolutegravir in Initial Therapy Ever Occur?
by: Mark eWainberg, et al.
Published: (2015-04-01)

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
by: Tony Antoniou, et al.
Published: (2017-04-01)

Rifampicin and anti-hypertensive drugs in chronic kidney disease: Pharmacokinetic interactions and their clinical impact
by: A Agrawal, et al.
Published: (2016-01-01)

Evaluation of the Side Effects of Antiretroviral Treatment
by: Sedef BAŞGÖNÜL, et al.
Published: (2018-12-01)

Two Strategies for the Dosage of Acenocoumarol Co-Administered with Rifampicin in Staphylococcal Prosthetic Valve Endocarditis
by: Marcin Wełnicki, et al.
Published: (2021-01-01)

Preparation and Characterization of Two Immunogens and Production of Polyclonal Antibody with High Affinity and Specificity for Darunavir
by: Ibrahim A. Darwish, et al.
Published: (2020-09-01)

Low plasmatic concentration of intensified antiretroviral therapy in a pregnant woman: a case report
by: Sheila Chiesi, et al.
Published: (2019-07-01)

Comparison of Tolerability and Impact on Metabolic Profiles of Antiretroviral Regimens Containing Darunavir/Ritonavir or Darunavir/Cobicistat in Romanian HIV Infected Patients
by: Ruxandra-Cristina Marin, et al.
Published: (2021-08-01)

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients
by: Restelli U, et al.
Published: (2017-06-01)

Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV
by: Charlotte-Paige Rolle, et al.
Published: (2021-05-01)

Unique Flap Conformation in an HIV-1 Protease with High-level Darunavir Resistance
by: Masaaki eNakashima, et al.
Published: (2016-02-01)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
by: Ruxandra-Cristina Marin, et al.
Published: (2021-03-01)

Darunavir-Resistant HIV-1 Protease Constructs Uphold a Conformational Selection Hypothesis for Drug Resistance
by: Zhanglong Liu, et al.
Published: (2020-11-01)

Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study
by: Antinori A, et al.
Published: (2016-05-01)

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study
by: Spagnuolo V, et al.
Published: (2019-01-01)

Data on the stability of darunavir/cobicistat suspension after tablet manipulation
by: D. Zanon, et al.
Published: (2020-06-01)

Clinical management of carbamazepine intoxication during anti-tubercular treatment: a case report
by: Massimo Calderazzo, et al.
Published: (2015-06-01)

HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: a systematic review and meta-analysis protocol
by: Ezechiel Ngoufack Jagni Semengue, et al.
Published: (2020-04-01)

Suicidal overdose of dolutegravir: A case report
by: Rahul Daimari, et al.
Published: (2018-06-01)

Changes in Inflammatory and Atherogenesis Biomarkers with the 2-Drug Regimen Dolutegravir plus Lamivudine in Antiretroviral Therapy–Experienced, Virologically Suppressed People with HIV-1: A Systematic Literature Review
by: Barber, T.J, et al.
Published: (2022)

The Effect of Solvents and Drying Temperature on the Physicochemical Properties of Darunavir and Darunavir Ethanolate Substances
by: S. A. Zolotov, et al.
Published: (2021-02-01)

Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks
by: Julián Olalla, et al.
Published: (2018-10-01)

Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study
by: Augusto Di Castelnuovo, et al.
Published: (2021-06-01)

Rifampicin resistance in Mycobacterium tuberculosis in Iran: a two-centre study
by: F. Bahraminia, et al.
Published: (2021-07-01)

Design of Mannose-Coated Rifampicin nanoparticles modulating the immune response and Rifampicin induced hepatotoxicity with improved oral drug delivery
by: Aisha Rauf, et al.
Published: (2021-09-01)

THE MOLECULAR GENETIC FEATURES OF RIFAMPICIN RESISTANCE AND THE PREVALENCE OF rpoB GENE MUTATIONS IN THE SARATOV REGION
by: T. Yu. Salina, et al.
Published: (2014-04-01)

Rifampicin-Induced Thrombocytopenia: A Case Report and Short Review of the Literature
by: Epameinondas Koumpis, et al.
Published: (2021-06-01)

Dolutegravir response in antiretroviral therapy naïve and experienced patients with M184V/I: Impact in low-and middle-income settings
by: Emmanuel Ndashimye, et al.
Published: (2021-04-01)

DOLUTEGRAVIR efficacy in HIV infected patients
by: Dumitru Irina Magdalena, et al.
Published: (2015-02-01)

Rifampicin resistance among patients with Tuberculosis at the Olabisi Onabanjo University Teaching Hospital, Sagamu
by: Daniel Olusoji James, et al.
Published: (2018-06-01)

Efficacy and safety of darunavir and etravirine in a patient with retroviruses and multiple virologic failure
by: Claudia Bernardini, et al.
Published: (2009-09-01)

Understanding Rifampicin Resistance in Tuberculosis through a Computational Approach
by: Satish Kumar, et al.
Published: (2014-12-01)

Careful consideration when responding to new data: dolutegravir and pregnancy
by: C. Foster, et al.
Published: (2018-07-01)